



Express Mail No. **EL984075019US**

**RESPONSE TO RESTRICTION
REQUIREMENT**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attorney Docket (Confirmation No.)	UCAL105CIP2 1732
First Named Inventor	Farese, R.
Application Number	10/040,315
Filing Date	October 29, 2001
Group Art Unit	1632
Examiner Name	Bertoglio, V.
Title: DIACYLGLYCEROL O-ACYLTRANSFERASE	

RECEIVED
SEP 30 2003
TECH CENTER 1600

Sir:

This is in response to the Restriction Requirement dated August 27, 2003. The Restriction Requirement set forth a one-month time period for response, making a response due on or before **September 27, 2003**. Accordingly, this response is timely filed.

I. REMARKS

In the Restriction Requirement, the Examiner required election of one of the following groups of claims:

- Group I: Claims 1-9 and 20-23, drawn to a non-human animal model having abnormal DGAT activity resulting from a DGAT genomic modification (claims 1-9); and an *in vivo* screening assay for determining a candidate agent's DGAT modulatory activity (claims 20-23);
- Group II: Claims 10-19 drawn to a cell having a disrupted endogenous DGAT locus (claims 10-14); and a screening assay for determining a candidate agent's DGAT modulatory activity (claims 15-19);
- Group III: Claims 24 and 26, drawn to an *in vitro* assay for screening candidate agents for modulatory activity of DGAT expression; and
- Group IV: Claim 24 and 27, drawn to an *in vivo* assay for screening candidate agents for modulatory activity of DGAT expression.

Applicants hereby elect to prosecute the claims of Group II (claims 10-19), with traverse. Applicants expressly reserve the right under 35 USC §121 to file one or more divisional applications directed to the non-elected subject matter during the pendency of this application.